CN1186022C - Medicine for teating oral disease - Google Patents
Medicine for teating oral disease Download PDFInfo
- Publication number
- CN1186022C CN1186022C CNB031096409A CN03109640A CN1186022C CN 1186022 C CN1186022 C CN 1186022C CN B031096409 A CNB031096409 A CN B031096409A CN 03109640 A CN03109640 A CN 03109640A CN 1186022 C CN1186022 C CN 1186022C
- Authority
- CN
- China
- Prior art keywords
- vitamin
- weight portion
- medicine
- present
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a topical medicine for treating oral diseases, such as ulceratiue stomatitis, periodontitis, tonsillitis, and mouth and tongue sores, which comprises at least one antibiotic selected from penicillin antibiotics and salts thereof, and cephalothin antibiotics and salts thereof. The present invention has a preferable scheme that the medicine comprises 30 to 95 portions by weight of at least one antibiotic selected from the penicillin antibiotics and the cephalothin antibiotics, and 5 to 25 portions by weight of at least one vitamin B selected from the vitamin B group.
Description
Invention field
The present invention relates to a kind of oral disease that is used for the treatment of, as the topical drug of oral ulcer, periodontitis, tonsillitis, aphtha of the mouth and tongue.
Background technology
Oral ulcer is the shallow table ulcer that takes place on oral mucosa, usually outbreak repeatedly.At the initial stage, small red dot appears in the oral mucosa congestion and edema, the circular or oval ulcer of festering soon, and surface coverage canescence film has redness on every side, and violent burning pain is arranged, and runs into the stimulation pain aggravation, influences patient and speaks and take food.
The present common drug of oral ulcer is a glucocorticoid medicine.But this class curative effect of medication is not remarkable, and treatment cycle is long.
Summary of the invention
The object of the present invention is to provide the treatment oral disease that a kind of pain relieving is rapid, healing time is short, especially the medicine of oral ulcer, the especially medicine of powder form.
The inventor is through repetition test, finds the powder for example of administration form beyond the penicillin medicine, and unguentum, forms such as cream directly deliver medicine to the oral cavity patient part, can eliminate patient's slight illness rapidly, and the short time demonstrates therapeutic effect.And this medicine with the powder form administering effect more.
More desirably, the inventor also finds through overtesting, with the penicillin medicine administration that combines with vitamin(e) B group, can eliminate patient's slight illness rapidly, and most oral cavity patient is reflected in 2 hours after the powder form administration 1 time and just feels that therapeutic effect is obvious.
One aspect of the present invention is that at least a antibiotic that is selected from Penicillin antibiotics and salt and cephalosporins and the salt thereof is treated oral disease in preparation, as the purposes in the topical drug of oral ulcer, periodontitis, tonsillitis, aphtha of the mouth and tongue.
Another aspect of the present invention is a kind of oral disease that is used for the treatment of, as the topical drug of oral ulcer, periodontitis, tonsillitis, aphtha of the mouth and tongue, by the 30-95 weight portion be selected from least a antibiotic in Penicillin antibiotics and the cephalosporins and at least a vitamin B except nicotiamide that is selected from the vitamin B complex of 5-25 weight portion is formed.
Another aspect of the present invention is that at least a antibiotic that is selected from Penicillin antibiotics and the cephalosporins is treated oral disease with at least a vitamin B that is selected from the vitamin B complex in preparation, as the purposes in the topical drug of oral ulcer, periodontitis, tonsillitis, aphtha of the mouth and tongue, wherein preceding a kind of component is respectively 30-95 and 5-25 with the weight portion of a kind of component in back.
In one embodiment, medicine of the present invention comprises at least a antibiotic that is selected from Penicillin antibiotics (salt that comprises them) and the cephalosporins (salt that comprises them) and at least a vitamin B that is selected from the vitamin B complex.
In a preferred embodiment, medicine of the present invention comprises at least a antibiotic in Penicillin antibiotics and the cephalosporins of being selected from of 30-95 weight portion, the 5-25 weight portion be selected from least a vitamin B in the vitamin B complex.
In another embodiment of the invention, medicine of the present invention comprises at least a antibiotic in Penicillin antibiotics and the cephalosporins of being selected from of 30-95 weight portion, the vitamin B2 of 5-25 weight portion.
In another embodiment of the invention, medicine of the present invention comprises at least a antibiotic in Penicillin antibiotics and the cephalosporins of being selected from of 30-95 weight portion, the vitamin B1 of 5-25 weight portion.
In another embodiment of the invention, medicine of the present invention comprises at least a antibiotic in Penicillin antibiotics and the cephalosporins of being selected from of 30-95 weight portion, the nicotiamide of 5-25 weight portion.
In another embodiment of the invention, medicine of the present invention comprises at least a antibiotic in Penicillin antibiotics and the cephalosporins of being selected from of 30-95 weight portion, the B2 of the vitamin B1 of 2.5-15 weight portion and 2.5-10 weight portion.
In yet another embodiment of the present invention, medicine of the present invention comprises at least a antibiotic in Penicillin antibiotics and the cephalosporins of being selected from of 30-95 weight portion, 2.5-15 the B2 of nicotiamide of weight portion (vitamin PP) and 2.5-10 weight portion.
In yet another embodiment of the present invention, medicine of the present invention comprises at least a antibiotic in Penicillin antibiotics and the cephalosporins of being selected from of 30-95 weight portion, 0.5-5 the B1 of weight portion, the nicotiamide of the B2 of 0.5-5 weight portion and 4-15 weight portion.
In yet another embodiment of the present invention, medicine of the present invention comprises at least a antibiotic in Penicillin antibiotics and the cephalosporins of being selected from of 30-95 weight portion, 0.5-5 the B1 of weight portion, 0.5-5 the B2 of weight portion, the nicotiamide of the B6 of 0.5-5 weight portion and 3.5-10 weight portion.
In yet another embodiment of the present invention, medicine of the present invention comprises at least a antibiotic in Penicillin antibiotics and the cephalosporins of being selected from of 30-95 weight portion, 0.5-5 the B1 of weight portion, 0.5-5 the B2 of weight portion, 0.5-5 the B6 of weight portion, the nicotiamide of the B12 of 0.0005-0.005 weight portion and 3.5-10 weight portion.
In another embodiment of the present invention, medicine of the present invention comprises at least a antibiotic in Penicillin antibiotics and the cephalosporins of being selected from of 30-95 weight portion, 0.5-3 the B1 of weight portion, 0.5-3 the B2 of weight portion, 0.5-3 the B6 of weight portion, 0.0005-0.005 the B12 of weight portion, the nicotiamide of the calcium pantothenate of 0.5-6 weight portion and 3-10 weight portion.
Penicillin antibiotics for example comprises the salt of benzylpenicillin and it, for example potassium salt or sodium salt, ampicillin, amoxicillin etc.
Cephalosporins for example comprises cefalexin, cefadroxil, cefradine, cefuroxime, cefixime, Cefpodoxime Proxetil etc.
In above all embodiments, medicine of the present invention can comprise other optional member, for example pharmaceutically acceptable carrier, as excipient, diluent, flavouring agent etc., starch for example, cellulose, modified cellulose is (as carboxymethyl cellulose, methylcellulose, hydroxypropyl cellulose), magnesium stearate, lactose, glycerol, vaseline etc.
Medicine of the present invention is most preferably with the local spray of the form of powder or smear usefulness.But also can cream, the ointment form topical application.The method for preparing these cream or ointment is known in those skilled in the art.
Amount of drug of the present invention changes according to the area and the number in affected part, and medicated powder should cover whole affected part usually.Per 30 minutes once, each an amount of, and one for several times.
Except oral ulcer, medicine of the present invention also is applicable to aphtha of the mouth and tongue, periodontitis, and tonsillitiss etc. all can reach extraordinary therapeutic effect.
Embodiment
Illustrate the present invention below in conjunction with embodiment, should be noted that, these embodiment only are used for illustrative purposes, do not limit the scope of the invention.
Reference example 1
With 250mg ampicillin and 10mg magnesium stearate mix homogeneously, make powder.
Embodiment 1
Five of commercial vitamin Bies (every 5mg) are pulverized,, made powder with 250mg ampicillin and 10mg magnesium stearate mix homogeneously.
Embodiment 2
50mg nicotiamide tablet is pulverized,, made powder with 4,000,000 unit penicillin G sodium salt mix homogeneously.
Embodiment 3
With the 5mg vitamin B1,10mg vitamin B2 and 15mg nicotiamide are pulverized, and with 4,000,000 unit penicillin G sodium salt mix homogeneously, make powder.
Embodiment 4
Commercial 1 of the expensive precious board Wei Kangfu that executes (is contained vitamin B1: 2mg, vitamin B2: 2mg, vitamin B6: 2mg, vitamin B12: 2ug, calcium pantothenate: 5mg, nicotiamide: 15mg) pulverize, mix with 4,000,000 unit penicillin G sodium salts, make powder.
Embodiment 5
Commercial 1 of the expensive precious board Wei Kangfu that executes (is contained vitamin B1: 2mg, vitamin B2: 2mg, vitamin B6: 2mg, vitamin B12: 2ug, calcium pantothenate: 5mg, nicotiamide: 15mg) pulverize, with the 250mg cephalexin, 10mg magnesium stearate and 200mg starch mix, and make powder.
Embodiment 6
Commercial 1 of the expensive precious board Wei Kangfu that executes (is contained vitamin B1: 2mg, vitamin B2: 2mg, vitamin B6: 2mg, vitamin B12: 2ug, calcium pantothenate: 5mg, nicotiamide: 15mg) pulverize, with 250mg cephazolin I, 10mg magnesium stearate and 200mg starch mix, and make powder.
Embodiment 7
Commercial 1 of the expensive precious board Wei Kangfu that executes (is contained vitamin B1: 2mg, vitamin B2: 2mg, vitamin B6: 2mg, vitamin B12: 2ug, calcium pantothenate: 5mg, nicotiamide: 15mg) pulverize, with 250mg cefaclor powder, 10mg magnesium stearate and 200mg starch mix, and make powder.
Embodiment 8
250mg cefradine and 50mg nicotiamide tablet are pulverized, made powder.
Embodiment 9
With the 250mg cefradine, 20mg vitamin B1 and 20mg vitamin B2 tablet are pulverized, and make powder.
Preferred dosage form
The product of the various embodiments described above is respectively charged in the plastic containers with 5-10ml, puts on vessel port or the conical sleeve of screwing on, a thick end docks with vessel port, and a thin end has very little mouth as nozzle.
Evaluation of clinical curative effect
The medicine that obtains with the above embodiment of the present invention is through 250 many cases patient clinic trial, the result shows, oral ulcer patient got final product pain relieving in 5-10 minute behind the spray medicine, the 2 hour just sensation ailing disappearances of patient after administration, general spray medicine 4-6 time, symptom can be eliminated, recovery from illness in 12 hours, and cure rate reaches 100%; For tonsillitis, periodontitis, also have pain relieving through topical application, accelerate the effect of recovery from illness.Wherein there is the preparation of vitamin B complex to demonstrate the effect for the treatment of oral disease more significantly, shows that mainly medicine promptly brings into play therapeutic effect, some months or even do not run into the phenomenon of recurrence in several years after the patient of reception test is reflected in and cures at present.
Claims (5)
1, is selected from the purposes of at least a antibiotic in the topical drug of preparation treatment oral disease in Penicillin antibiotics and salt thereof and cephalosporins and the salt thereof.
2, a kind of topical drug that is used for the treatment of oral disease, by the 30-95 weight portion be selected from least a antibiotic in Penicillin antibiotics and the cephalosporins and at least a vitamin B except nicotiamide that is selected from the vitamin B complex of 5-25 weight portion is formed.
3, according to the topical drug of claim 2, wherein said vitamin B is vitamin B2 or B1.
4, according to the topical drug of claim 2, wherein said vitamin B comprises the vitamin B1 of 2.5-15 weight portion and the B2 of 2.5-10 weight portion.
5, be selected from least a antibiotic in Penicillin antibiotics and the cephalosporins and be selected from the purposes of at least a vitamin B in the topical drug of preparation treatment oral disease in the vitamin B complex, wherein before the weight portion of a kind of component and a kind of component in back be respectively 30-95 and 5-25.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031096409A CN1186022C (en) | 2003-04-11 | 2003-04-11 | Medicine for teating oral disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031096409A CN1186022C (en) | 2003-04-11 | 2003-04-11 | Medicine for teating oral disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1446539A CN1446539A (en) | 2003-10-08 |
| CN1186022C true CN1186022C (en) | 2005-01-26 |
Family
ID=28050259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031096409A Expired - Fee Related CN1186022C (en) | 2003-04-11 | 2003-04-11 | Medicine for teating oral disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1186022C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940616A (en) * | 2015-05-28 | 2015-09-30 | 王玉波 | Traditional Chinese medicine ointment for treating herpes type recurrent oral ulcer |
| CN109745563B (en) * | 2019-01-09 | 2021-04-16 | 复旦大学 | SIRT1 inhibitor for preventing and treating oral cavity injury caused by radiation |
-
2003
- 2003-04-11 CN CNB031096409A patent/CN1186022C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1446539A (en) | 2003-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ286202B6 (en) | Compound pharmaceutical preparation exhibiting inhibition properties to lipase and use of acarbose for preparing thereof | |
| EP1841432B1 (en) | Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection | |
| Swabb et al. | Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects | |
| CN1289084C (en) | Pharmaceutical formulation | |
| EP3452018A2 (en) | Effervescent formulations comprising cefaclor and clavulanic acid as active agents | |
| CN1233958A (en) | Use of combination of amoxycillin and clavulanate in mfg. medicament for treatment drug-resistant streptococcus pneumonia | |
| DE69425131T2 (en) | USE OF CLAVULIC ACID AND AN ANTIBIOTIC FOR TREATING INFECTIONS | |
| JPH0692850A (en) | Remedy for gastrointestinal disturbance | |
| CN1186022C (en) | Medicine for teating oral disease | |
| WO2022028243A1 (en) | Use of compound amino acids in preparation of drugs enhancing sensitivity of bacteria to antibiotics | |
| Jewesson | Pharmaceutical, pharmacokinetic and other considerations for intravenous to oral stepdown therapy | |
| JPH0656679A (en) | Prophylactic and therapeutic composition for clostridium difficile diarrhea and pseudomembranous colitis | |
| WO2006025767A2 (en) | Perorally administrable antimicrobial composition | |
| CN1092986C (en) | CoA oral preparation for reducing blood fat and its preparation method | |
| Lode et al. | Comparative pharmacokinetics of the new oral cephalosporins | |
| CN1729983A (en) | Pharmaceutical composition of cefadroxil and beta-lactamase inhibitor | |
| CN102846605B (en) | Medicinal composition, as well as preparation process and application thereof | |
| CN1546020A (en) | Vaginal effervescence tablet of secnidazole and its preparation | |
| CN1236814C (en) | Faropenem pharmaceutical composition containing glutathione | |
| Leder et al. | Cefuroxime Axetil (Ceftin®): a brief review | |
| US20210069183A1 (en) | Composition containing piperacillin, pharmaceutical formulation thereof and use thereof | |
| CN1304725A (en) | Antibacterial cephalosporin composition | |
| CN1224390C (en) | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver | |
| CN1895274A (en) | Calf-blood deprotein capsules and preparation thereof | |
| CN1843372A (en) | Pharmaceutical compositions separately constituted by ambroxol and two other antibacterials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |